Literature DB >> 21841015

microRNA-210 is upregulated in hypoxic cardiomyocytes through Akt- and p53-dependent pathways and exerts cytoprotective effects.

R Kannan Mutharasan1, Varun Nagpal, Yoshihiko Ichikawa, Hossein Ardehali.   

Abstract

microRNA-210 (miR-210) is upregulated in hypoxia, but its function in cardiomyocytes and its regulation in response to hypoxia are not well characterized. The purpose of this study was to identify upstream regulators of miR-210, as well as to characterize miR-210's function in cardiomyocytes. We first showed miR-210 is upregulated through both hypoxia-inducible factor (HIF)-dependent and -independent pathways, since aryl hydrocarbon nuclear translocator (ARNT) knockout mouse embryonic fibroblasts (MEF), lacking intact HIF signaling, still displayed increased miR-210 levels in hypoxia. To determine the mechanism for HIF-independent regulation of miR-210, we focused on p53 and protein kinase B (Akt). Overexpression of p53 in wild-type MEFs induced miR-210, whereas p53 overexpression in ARNT knockout MEFs did not, suggesting p53 regulates miR-210 in a HIF-dependent mechanism. Akt inhibition reduced miR-210 induction by hypoxia, whereas Akt overexpression increased miR-210 levels in both wild-type and ARNT knockout MEFs, indicating Akt regulation of miR-210 is HIF-independent. We then studied the effects of miR-210 in cardiomyocytes. Overexpression of miR-210 reduced cell death in response to oxidative stress and reduced reactive oxygen species (ROS) production both at baseline and after treatment with antimycin A. Furthermore, downregulation of miR-210 increased ROS after hypoxia-reoxygenation. To determine a mechanism for the cytoprotective effects of miR-210, we focused on the predicted target, apoptosis-inducing factor, mitochondrion-associated 3 (AIFM3), known to induce cell death. Although miR-210 reduced AIFM3 levels, overexpression of AIFM3 in the presence of miR-210 overexpression did not reduce cellular viability either at baseline or after hydrogen peroxide treatment, suggesting AIFM3 does not mediate miR-210's cytoprotective effects. Furthermore, HIF-3α, a negative regulator of HIF signaling, is targeted by miR-210, but miR-210 does not modulate HIF activity. In conclusion, we demonstrate a novel role for p53 and Akt in regulating miR-210 and demonstrate that, in cardiomyocytes, miR-210 exerts cytoprotective effects, potentially by reducing mitochondrial ROS production.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21841015      PMCID: PMC3197368          DOI: 10.1152/ajpheart.01080.2010

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  42 in total

1.  MicroRNAs in angiogenesis and vascular smooth muscle cell function.

Authors:  Susan Daubman
Journal:  Circ Res       Date:  2010-02-19       Impact factor: 17.367

Review 2.  Role of microRNAs in cardiac hypertrophy and heart failure.

Authors:  Nan Wang; Zhen Zhou; Xinghua Liao; Tongcun Zhang
Journal:  IUBMB Life       Date:  2009-06       Impact factor: 3.885

3.  Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation.

Authors:  Xin Huang; Lianghao Ding; Kevin L Bennewith; Ricky T Tong; Scott M Welford; K Kian Ang; Michael Story; Quynh-Thu Le; Amato J Giaccia
Journal:  Mol Cell       Date:  2009-09-24       Impact factor: 17.970

4.  MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU.

Authors:  Elena Favaro; Anassuya Ramachandran; Robert McCormick; Harriet Gee; Christine Blancher; Meredith Crosby; Cecilia Devlin; Christopher Blick; Francesca Buffa; Ji-Liang Li; Borivoj Vojnovic; Ricardo Pires das Neves; Peter Glazer; Francisco Iborra; Mircea Ivan; Jiannis Ragoussis; Adrian L Harris
Journal:  PLoS One       Date:  2010-04-26       Impact factor: 3.240

5.  Modulation of microRNA processing by p53.

Authors:  Hiroshi I Suzuki; Kaoru Yamagata; Koichi Sugimoto; Takashi Iwamoto; Shigeaki Kato; Kohei Miyazono
Journal:  Nature       Date:  2009-07-23       Impact factor: 49.962

6.  The human HIF (hypoxia-inducible factor)-3alpha gene is a HIF-1 target gene and may modulate hypoxic gene induction.

Authors:  Tetsuhiro Tanaka; Michael Wiesener; Wanja Bernhardt; Kai-Uwe Eckardt; Christina Warnecke
Journal:  Biochem J       Date:  2009-10-23       Impact factor: 3.857

Review 7.  Akt mediated mitochondrial protection in the heart: metabolic and survival pathways to the rescue.

Authors:  Shigeki Miyamoto; Anne N Murphy; Joan Heller Brown
Journal:  J Bioenerg Biomembr       Date:  2009-04       Impact factor: 2.945

8.  MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT.

Authors:  Zhan Zhang; Hong Sun; Hongyue Dai; Ryan M Walsh; Maki Imakura; Janell Schelter; Julja Burchard; Xudong Dai; Aaron N Chang; Robert L Diaz; Joseph R Marszalek; Steven R Bartz; Michael Carleton; Michele A Cleary; Peter S Linsley; Carla Grandori
Journal:  Cell Cycle       Date:  2009-09-29       Impact factor: 4.534

9.  MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2.

Authors:  Stephen Y Chan; Ying-Yi Zhang; Craig Hemann; Christopher E Mahoney; Jay L Zweier; Joseph Loscalzo
Journal:  Cell Metab       Date:  2009-10       Impact factor: 27.287

10.  Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2.

Authors:  Ha Won Kim; Husnain K Haider; Shujia Jiang; Muhammad Ashraf
Journal:  J Biol Chem       Date:  2009-08-31       Impact factor: 5.157

View more
  80 in total

1.  Function and clinical potential of microRNAs in hepatocellular carcinoma.

Authors:  Lijuan Wang; Yongfang Yue; Xian Wang; Hongchuan Jin
Journal:  Oncol Lett       Date:  2015-09-29       Impact factor: 2.967

2.  miR-210 promotes IPF fibroblast proliferation in response to hypoxia.

Authors:  Vidya Bodempudi; Polla Hergert; Karen Smith; Hong Xia; Jeremy Herrera; Mark Peterson; Wajahat Khalil; Judy Kahm; Peter B Bitterman; Craig A Henke
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-06-20       Impact factor: 5.464

Review 3.  MicroRNAs in the thyroid.

Authors:  Myriem Boufraqech; Joanna Klubo-Gwiezdzinska; Electron Kebebew
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2016-11-01       Impact factor: 4.690

Review 4.  HypoxamiRs and cancer: from biology to targeted therapy.

Authors:  Harriet E Gee; Cristina Ivan; George A Calin; Mircea Ivan
Journal:  Antioxid Redox Signal       Date:  2013-11-22       Impact factor: 8.401

Review 5.  Gestational hypoxia and epigenetic programming of brain development disorders.

Authors:  Qingyi Ma; Fuxia Xiong; Lubo Zhang
Journal:  Drug Discov Today       Date:  2014-09-26       Impact factor: 7.851

6.  Protective effect of miR-20a against hypoxia/reoxygenation treatment on cardiomyocytes cell viability and cell apoptosis by targeting TLR4 and inhibiting p38 MAPK/JNK signaling.

Authors:  Xin-Yu Gong; Yun Zhang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2019-08-23       Impact factor: 2.416

Review 7.  MicroRNAs in myocardial ischemia: identifying new targets and tools for treating heart disease. New frontiers for miR-medicine.

Authors:  V Sala; S Bergerone; S Gatti; S Gallo; A Ponzetto; C Ponzetto; T Crepaldi
Journal:  Cell Mol Life Sci       Date:  2013-11-12       Impact factor: 9.261

Review 8.  OxymiRs in cutaneous development, wound repair and regeneration.

Authors:  Chandan K Sen; Sashwati Roy
Journal:  Semin Cell Dev Biol       Date:  2012-10-10       Impact factor: 7.727

Review 9.  Hypoxia: a master regulator of microRNA biogenesis and activity.

Authors:  Shriram Nallamshetty; Stephen Y Chan; Joseph Loscalzo
Journal:  Free Radic Biol Med       Date:  2013-05-24       Impact factor: 7.376

Review 10.  Therapeutic Potential of Modulating MicroRNA in Peripheral Artery Disease.

Authors:  Naomi M Hamburg; Nicholas J Leeper
Journal:  Curr Vasc Pharmacol       Date:  2015       Impact factor: 2.719

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.